Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 3/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.41 |
| ▸ | WNT1 | P04628 | 2/20 | 0.40 |
| ▸ | CSNK1D | P48730 | 5/20 | 0.40 |
| ▸ | CSNK1E | P49674 | 5/20 | 0.40 |
| ▸ | KDR | P35968 | 5/20 | 0.39 |
| ▸ | CTSK | P43235 | 2/20 | 0.38 |
| ▸ | CTSC | P53634 | 2/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | TYK2 | P29597 | 2/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5955316 | 0.93 | GSK3B (0.39) | GSK3BDYRK1AWNT1CSNK1DCSNK1E | |
| SCHEMBL5954621 | 0.92 | CSNK1D (0.41) | GSK3BDYRK1AWNT1CSNK1DCSNK1E | |
| SCHEMBL5955110 | 0.90 | GSK3B (0.36) | GSK3BDYRK1AWNT1CSNK1DCSNK1E | |
| SCHEMBL252642 | 0.88 | GSK3B (0.46) | GSK3BDYRK1AWNT1CSNK1DCSNK1E | |
| SCHEMBL252643 | 0.88 | GSK3B (0.46) | GSK3BDYRK1AWNT1CSNK1DCSNK1E | |
| SCHEMBL252743 | 0.88 | GSK3B (0.46) | GSK3BDYRK1AWNT1CSNK1DCSNK1E | |
| SCHEMBL5955461 | 0.87 | CCNC (0.43) | GSK3BDYRK1AWNT1CSNK1DCSNK1E | |
| SCHEMBL5955466 | 0.84 | CSNK1D (0.36) | GSK3BDYRK1AWNT1CSNK1DCSNK1E | |
| SCHEMBL5954813 | 0.84 | GSK3B (0.42) | GSK3BDYRK1AWNT1CSNK1DCSNK1E | |
| SCHEMBL252764 | 0.84 | JAK1 (0.51) | GSK3BCSNK1DCSNK1EKDRTYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178534-B2 | cMET inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-15 | — | — | US | disclosed |
| US-8178534-B2 | cMET inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-15 | — | — | US | disclosed |
| US-20100063054-A1 | cMET INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-11 | — | — | US | disclosed |
| US-20100063054-A1 | cMET INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063054-A1 | cMET INHIBITORS | CEPT1, LCAT, GNMT | GSK3B 35/4885DYRK1A 4332/4885WNT1 2494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.